The drug 5-fluorouracil (5-FU) is a pyrimidine antagonist used for chemotherapy. Cardiotoxicity is a rare side effect of this compound (1). We present two cases of 5-FU cardiotoxicity, because every cardiologist has to be aware of the possible clinical presentations and its management as it can be life threatening.
arm in ice-cold water, resulted in 30-40% narrowing of the Cx artery (Fig. 2b) .
The patient's chemotherapy regime was changed. She was discharged on oral diltiazem 90 mg/day. She remained free of any cardiac symptoms in follow-up.
Our second case is a 63-year-old man who had coronary artery disease. He had adenocarcinoma of the duodenum and was started i.v. 5-FU (425 mg/m 2 /day) and folinic acid (25 mg/m 2 /day). On the 3rd day of the regimen shortly after the continuous infusion of 5-FU, the patient developed chest pain with ST segment elevation in leads II, III, aVF, V4, V5 and V6 (Fig. 3A) . He was admitted to CCU and i.v. nitroglycerine and diltiazem infusion was started. The ST segment changes ( A coronary angiography was performed, which revealed atherosclerotic plaques in LAD and circumflex arteries. The right coronary artery was non dominant and was totally occluded in its proximal part.
Vasospasm was not observed with hyperventilation-induced respiratory alkalosis or the cold pressor test.
He was discharged on oral nitrate and diltiazem. He received a different chemotherapy regimen with no 5-FU.
Discussion
Cases of mild precordial pain with ST segment and/or T-wave changes, myocardial infarction, left ventricular failure, cardiogenic shock, ventricular and supraventricular arrhythmias, and sudden cardiac death have been reported (2-6) in >20% of patients receiving 5-FU. The underlying pathophysiological mechanism remains unclear. Coronary vasospasm may play a role in the pathogenesis. More than 60% of patients respond to conventional antianginal therapy (7) .
Discontinuation of 5-FU infusion and immediate administration of sublingual nitrate is the life saving first line of therapy in the treatment of cardiovascular complications of 5-FU. As the symptoms may continue even after cessation of 5-FU administration, the patients should be followed for at least 72 hours in coronary care units. Patients with known CAD are more at risk, therefore should be followed more closely with a high level of alertness. The chemotherapy regimen of these patients should be changed. Patients should be evaluated for cardiovascular risk factors and managed accordingly in the follow-up. 
